Geron's RYTELO Shows Real-World Efficacy in LR-MDS, Expanding Patient Reach — Geron Corporation

Event summary

Geron to present real-world data on RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) at EHA 2026, showing 37.5% transfusion independence in heavily pretreated patients.
Study conducted at Moffitt Cancer Center included 40 patients with advanced, transfusion-dependent disease and extensive prior therapies.
Additional data presentations at EHA and ASCO 2026 will cover myelofibrosis and AML clinical programs.
RYTELO approved in U.S. and EU for LR-MDS with transfusion-dependent anemia.

The big picture

Geron's real-world data presentation at EHA 2026 underscores the growing importance of post-approval evidence in oncology. The study's focus on heavily pretreated LR-MDS patients highlights the strategic value of demonstrating efficacy in broader, more challenging patient populations. This positions RYTELO as a potential standard of care in treatment sequencing for LR-MDS, potentially expanding its market reach beyond current approved indications.

What we're watching

Treatment Sequencing: Whether early use of RYTELO within first three lines of therapy improves outcomes in LR-MDS patients.
Regulatory Expansion: The pace at which Geron can expand RYTELO's approved indications based on real-world evidence.
Competitive Positioning: How RYTELO's efficacy in heavily pretreated patients positions it against competitors like luspatercept.